Multiplex molecular diagnostics built for practical deployment.
Papyrus Diagnostics develops molecular diagnostic platforms for tuberculosis and related infections. Its lead system, Papyrus MutaCheck Pro, combines identity and drug-resistance detection in a single workflow using existing PCR infrastructure.
Built to close the gap between molecular insight and routine use.
Molecular diagnostics can generate high-value clinical information, but many workflows remain expensive, fragmented, or difficult to deploy in routine settings. Papyrus is building systems that make advanced molecular testing more practical without requiring new dedicated infrastructure.
Papyrus MutaCheck Pro
A consumables-led molecular diagnostic platform for tuberculosis identification and drug-resistance detection.
Designed to distinguish Mycobacterium tuberculosis from non-tuberculous mycobacteria and detect key drug-resistance mutations in one workflow. Amplification is performed on existing PCR blocks, and results are read using a proprietary closed-tube strip and compact reader.
Why it matters
Faster answers
Combines identity and resistance-linked information in a single test workflow.
Lower infrastructure burden
Works with existing PCR systems and avoids the need for a new dedicated molecular instrument.
Cleaner operation
Uses a closed-tube strip format to reduce post-PCR handling and lower contamination risk.
From amplification to mutation calling
A modular diagnostics platform with integrated systems and standalone components.
Papyrus MutaCheck Pro
Lead molecular diagnostics system for tuberculosis and resistance-linked detection.
DetectFlow
Nucleic acid lateral flow detection platform for molecular readout.
DetectGold
Gold nanoparticle reagent system for diagnostic signal generation.
Papyrus ImmunoCheck
An extension of the Papyrus platform for antigen and antibody-based testing.
A platform, not a one-product company
MutaCheck Pro is the first integrated application of the Papyrus platform. DetectFlow and DetectGold represent commercialized enabling products within the same stack, while ImmunoCheck extends the platform into adjacent diagnostic formats.
Validation
In a blinded feasibility study at NIRT Chennai, Papyrus MutaCheck Pro showed strong early performance for tuberculosis detection and rifampicin resistance detection, supporting further validation.
Provisional patent filed
Core aspects of the multiplexed nucleic acid detection platform filed through IISc Bangalore.
Supported by leading ecosystems
Recognition from BIRAC, C-CAMP, Honeywell, and other deeptech and biotech support networks.
Built at the intersection of diagnostics and engineering.
Papyrus Diagnostics is a deeptech startup based in Bengaluru and an academic spin-off from IISc Bangalore. The company develops molecular diagnostic platforms for tuberculosis and related infections, with a focus on making high-information testing easier to deploy in real-world care settings.
Built by a team spanning diagnostics and engineering
Venkata Subramanian Ramesan
Leads company building, product translation, and execution across diagnostics, workflow design, and market development.
Dr. Bhushan Toley
Faculty at IISc Bangalore with expertise in diagnostics, paper microfluidics, and translational bioengineering.
Supported by leading biotech and deeptech ecosystems
Practical molecular diagnostics with a clear lead product and a broader platform architecture.
For investor discussions, strategic partnerships, and technical conversations, contact the team.